$NOVO B (+5,32 %)
$NVO (+5,14 %)
Novo Nordisk has announced positive results from its phase 1b/2a trial for amycretin, a novel GLP-1 and amylin receptor agonist designed for once-weekly subcutaneous use. The trial, involving 125 participants with overweight or obesity, demonstrated significant weight loss potential over 36 weeks:
- 9.7% weight loss at 1.25 mg (20 weeks)
- 16.2% weight loss at 5 mg (28 weeks)
- 22.0% weight loss at 20 mg (36 weeks)
- Placebo groups experienced weight gains of up to 2.3%.
The treatment showed a safety profile consistent with incretin-based therapies, with most adverse events being mild to moderate gastrointestinal issues.
Encouraged by these findings, Novo Nordisk plans to advance amycretin's clinical development for obesity and type 2 diabetes treatment.
